Summary:
In patients with diabetes who received drug-eluting stent (DES) implantation, indobufen-based dual antiplatelet therapy (DAPT) significantly reduced bleeding risk compared to aspirin-based DAPT, though it was associated with similar efficacy in preventing ischemic events.
| PICO | Description |
|---|---|
| Population | Patients with diabetes undergoing drug-eluting stent (DES) implantation for coronary artery disease. |
| Intervention | Indobufen-based dual antiplatelet therapy (DAPT). |
| Comparison | Aspirin-based dual antiplatelet therapy (aspirin plus clopidogrel). |
| Outcome | Indobufen-based DAPT resulted in reduced bleeding risk compared to aspirin-based DAPT, with comparable levels of ischemic event prevention. |
Source: Shujing Wu, et al. “Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial.” Read article here.
